Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Evolus, Inc.

Evolus, Inc. (EOLS) Stock Overview

Explore Evolus, Inc.’s financial performance, market position, analyst ratings, and future outlook.

EOLS●NASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$9.05
$0.010(0.11%)
U.S. Market opens in 7h 15m

Evolus, Inc. (EOLS)

Meyka AI Score

Z

Key Financials

Market Cap596M
P/E Ratio-17.36
EPS (TTM)$-0.32
ROE1.23%
Fundamental Analysis

AI Price Forecasts

1 Month$7.89
3 Months$6.66
1 Year Target$0.87

EOLS Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Evolus, Inc. (NASDAQ: EOLS) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Evolus, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of EOLS on the NASDAQ shows an RSI of 69.68, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $0.87 for the NASDAQ listing.

Key metrics behind Evolus, Inc.'s NASDAQ-traded stock include a P/E ratio of -17.36 and a market capitalization of 596M. Combined with our AI analysis, these give both institutional and retail investors a clear view of EOLS on the NASDAQ.

Price Performance (NASDAQ: EOLS)

1-Day Change
-0.11%
5-Day Change
2.38%
1-Month Change
49.59%
3-Month Change
50.08%
6-Month Change
119.13%
Year-to-Date (YTD) Change
36.09%
1-Year Change
22.63%
3-Year Change
-6.99%
5-Year Change
-5.93%
All-Time (Max) Change
-21.30%

Contact Information

https://www.evolus.com
949 284 4555
520 Newport Center Drive, Newport Beach, CA, 92660

Company Facts

3,530 Employees
IPO DateFeb 8, 2018
CountryUS
Actively Trading

Frequently Asked Questions